Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
The 24-week extension of AIDS Clinical Trials Group Protocol 359, a study of human immunodeficiency virus (HIV)-infected, indinavir-experienced patients, was designed to study the durability of "salvage" treatment regimens. Patients received saquinavir in combination with either ritonavir or nelfinavir and, in addition, delavirdine, adefovir, or both. Patients who demonstrated a virologic response at weeks 12-16 were eligible to continue therapy in the extension through week 48. Of the 105 eligible subjects who were enrolled in the extension, 86 (82%) completed 48 weeks, and 49 (57%) of those 86 had HIV RNA levels <or=500 copies/mL at week 48. For these 86 subjects who completed 48 weeks, the median change in CD4 cell count from baseline was +72 cells/mm(3). Greater body weight, higher CD4 cell count, and greater degree of phenotypic susceptibility to indinavir and saquinavir at baseline were significantly associated with durable virologic suppression. These results show that some patients who experience treatment failure can demonstrate durable virologic and immunologic responses with salvage antiretroviral regimens.
Weill Medical College of Cornell University, New York, New York 10021, USA. rgulick@med.cornell.edu
Roy M
RM
Gulick
X Joan
XJ
Hu
Susan A
SA
Fiscus
Courtney V
CV
Fletcher
Richard
R
Haubrich
Hailong
H
Cheng
Edward
E
Acosta
Stephen W
SW
Lagakos
Ronald
R
Swanstrom
William
W
Freimuth
Sally
S
Snyder
Charlotte
C
Mills
Margaret
M
Fischl
Carla
C
Pettinelli
David
D
Katzenstein
D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D020008:Delavirdine / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use; D016879:Salvage Therapy; D019258:Saquinavir / Q000627:therapeutic use
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D020008:Delavirdine; D019258:Saquinavir; D019438:Ritonavir